Astatine-211: Production and availability

Current Radiopharmaceuticals

Volumn 4, Issue 3, 2011, Pages 177-185

  Zalutsky, Michael R ^a   Pruszynski, Marek ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astatine 211; Cyclotron; Radionuclide; Targeted radiotherapy; particle

Indexed keywords

ASTATINE 211; BISMUTH;

ALPHA RADIATION; ARTICLE; CYCLOTRON; DRUG SYNTHESIS; PARTICLE RADIATION; PRIORITY JOURNAL; RADIATION ENERGY; RADIOISOTOPE THERAPY;

EID: 79959430516     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104030177     Document Type: Article

References (40)

1. Zalutsky, M.R.: Radionuclide therapy. In: Handbook of Nuclear Chemistry: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences Roesch, F., Ed., Kluwer Academic: Dordrecht, Netherlands, 2003, Volume 4, pp. 315-348.
2. Zalutsky, M.R.; Vaidyanathan, G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Current Pharm. Design, 2000, 6, 1433-1455.
3. Vaidyanathan, G.; Zalutsky, M.R. Astatine radiopharmaceuticals: prospects and problems. Current Radiopharm., 2008, 1, 177-196.
4. Milesz, S.; Norseev, Y.V.; Szücs, Z.; Vasáros, L. Characterization of DTPA complexes and conjugated antibodies of astatine. J. Radioanal. Nucl. Chem. Lett., 1989, 137, 365-372.
5. 211At-calix[4]arene complex. J. Label. Compd. Radiopharm., 2000, 43, 1219-1225.
6. 211At via a tin precursor. Bioconjugate Chem., 2006, 17, 195-203.
7. 211At labeling of protein. Nucl. Med. Biol., 2006, 33, 469-480.
8. Wilbur, D. S.; Chyan, M. K.; Hamlin, D. K.; Vessella, R. L.; Wedge, T. J.; Hawthorne, M. F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjugate Chem., 2007, 18, 1226-1240.
9. 211At-labeled monoclonal antibodies. Nucl. Med. Biol.; 2007, 34, 779-785.
10. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl. Med. Biol., 1995, 22, 45-54.
11. 211At-labeled chimeric 81C6 anti-tenascin monoclonal antibody. J. Nucl. Med., 2008, 49, 30-38.
12. 2-phase I study J. Nucl. Med., 2009, 50, 1153-1160.
13. th Edition, Springer-Verlag: Berlin, 1985, pp. 95-106.
14. Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods, Technical Reports Series Number 468, International Atomic Energy Agency: Vienna, 2009, pp. 33-40.
15. Harrison, J.; Leggett, R.: Lloyd, L.; Phipps, A.; Scott, B. Polonium-210 as a poison. J. Radiol. Prot., 2007, 27, 17-40.
16. 211At. Appl. Radiat. Isot., 2001, 54, 839-844.
17. 211At on the cyclotron U-120M. Int. J. Appl. Radiat. Isot., 2005, 63, 49-53.
18. 211At reaction. Appl. Radiat. Isotop., 1996, 47, 135-143.
19. 211At produced in disposable internal and external bismuth targets. Nucl. Med. Biol., 1998, 25, 89-93.
20. 209Bi. Int. J. Appl. Radiat. Isot., 2005, 63, 1-9.
21. Groppi, F.; Bonardi, M.L.; Birattari, C.; Menapace, E.; Abbas, K.; Holzwarth, U.; Alfarano, A.; Morzenti, S.; Zona, C.; Alfassi, Z.B. Optimisation study of O-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes. Int. J. Appl. Radiat. Isot., 2005, 63, 621-631.
22. 209Bi(B,2n). J. Phys. Conf. Series, 2006, 41, 115-122.
23. ICRP 1990 Recommendations of the International Commission on Radiological Protection Ann. ICRP 1991, 21, Oxford: Elsevier, (1-3).
24. 211Atlabeled antibodies for clinical use. J. Nucl. Med., 2001, 42, 1508-1515.
25. th Edition, Springer-Verlag: Berlin, 1985, pp. 183-209.
26. 209Bi target for radiopharmaceutical applications. J. Radioanalyt. Nucl. Chem., 2004, 262, 593-599.
27. Champion, J.; Alliot, C.; Huclier, S.; Deniaud, D.; Asfari, Z.; Montavon, G. Determination of stability constants between complexing agents and At(I) and At(III) species present at ultra-trace concentrations. Inorganica Chimica. Acta, 2009, 362, 2654-2661.
28. Champion, J.; Alliot, C.; Renault, E.; Molkili, B.M.; Chérel, M.; Galland, N.; Montavon, G. Astatine standard redox potentials and speciation in acidic medium. J. Phys. Chem., A 2010, 114, 576-582.
29. Roy, K.; Basu, S.; Ramaswami, A.; Nayak, D.; Lahiri, S. Incorporation of thiosemicarbazide in Amberlite IRC-50 for separation of astatine from a-irradiated bismuth oxide. Appl. Radiat. Isotop., 2004, 60, 793-799.
30. Lindegren, S.; Back, T.; Jensen, H.J. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl. Radiat. Isot., 2001, 55, 157-160.
31. Lambrecht, R.M.; Mirzadeh, S. Cyclotron isotopes and radiopharmaceuticals-XXXV. Astatine-211. Int. J. Appl. Radiat. Isotop., 1985, 36, 443-450.
32. Friedman, A.M.; Zalutsky, M.R.; Wung, W.; Buckinham, F.; Harper, P.V., Jr.; Scherr, G.H., Wainer, B.; Hunter, R.L.; Appelman, E.H.; Rothberg, R.M.; Fitch, F.W.; Stuart, F.P.; Simonian, S.J. Preparation of a biologically stable and immunogenically competent astatinated protein. Int. J. Nucl. Med. Biol., 1977, 4, 219-224.
33. Pozzi, O.R.; Zalutsky, M.R. Radiopharmaceutical chemistry of targeted radiotherapeutics III: solvent and radiation dose effects on astatination chemistry at high radiation doses of astatine-211 t-particles. J. Nucl. Med., 2007, 48, 1190-1206.
34. Pozzi, O.R.; Zalutsky, M.R. Radiopharmaceutical chemistry of targeted radiotherapeutics I: Effects of solvent on the degradation of radiohalogenation precursors by astatine-211 o-particles. J. Nucl. Med., 2005, 46, 700-706.
35. Barbet, J.; Chatal, J.-F.; Gauché, F.; Martino, J. Which radionuclides will nuclear oncology need tomorrow? Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 627-630.
36. National Research Council and Institute of Medicine. Advancing Nuclear Medicine through Innovation, National Academy Press: Washington, DC, 2007.
37. Harris, T.J.R.; Kalen, J.D.; Hall, J. Report of Meeting Held to Discuss Existing and Future Radionuclide Requirements for the National Cancer Institute, Science Applications International Corporation: Frederick, MD, 2008.
38. Haddad, F.; Ferrer, L.; Guertin, A.; Carlier, T.; Michel, N.; Barbet, J.; Chatal, J.-F. ARRONAX, a high-energy, high-intensity cyclotron for nuclear medicine. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1377-1387.
39. Directory of Cyclotrons used for Radionuclide Production in Member States: 2006 Update, Report Number IAEA-DCRP/2006, IAEA:Vienna, 2006.
40. Cômar, J.J.; Beter, G.-J.; Pimentel-Gonzalez, G. Production of radioiodines with medical PET cyclotrons. In: Trends in Radiopharmaceuticals, International Atomic Energy Agency: Vienna, 2007, pp.209-222.